Endometriosis Trial, Recruiting NCT05152264 Sponsor: Göteborg University Condition: Endometriosis
Back to Endometriosis

Endometriosis Trial, Recruiting

NCT05152264
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 18 years of age or older
  • People who are willing to give their consent to take part in the study
  • People who have had endometriosis confirmed by keyhole surgery (laparoscopy) or ultrasound
  • People who have had ongoing pain related to endometriosis for more than 3 months and are available to receive TENS treatment (a device that uses mild electrical signals to help manage pain)
  • People who are on a stable hormonal medication specifically for endometriosis, where that medication has not changed in the last 3 months, and where no surgical procedures for endometriosis are planned in the next 7 months

Who may not be able to join:

  • People who are unable to understand or use written and spoken Swedish
  • People who have a pacemaker, an implantable defibrillator (ICD), or any other electronic implant in their body
  • People who have reduced or altered feeling/sensation over the area where they experience pain
  • People who have a serious illness (such as cancer) where life expectancy is expected to be less than 12 months
  • People with a current alcohol or substance abuse problem
  • People with a serious, untreated psychiatric or psychological condition that is considered the main cause of their symptoms
  • People who are already taking part in another intervention study that could affect the results of this trial
  • People who are using high-dose opioid pain medication above a certain threshold (more than 90 morphine equivalents per day) (confirm with trial site)
  • People who are currently receiving electro-acupuncture treatment
  • People who are pregnant

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Paulin Andéll, MD, Göteborgs Universitet/Västra Götalands Regionen

Phone: +46-31-3438259

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Göteborg University
Registry
ClinicalTrials.gov
Start date
12 November 2021
Est. completion
1 December 2027

Where this trial is recruiting

🇸🇪 Sweden

Primary endpoints

Pain intensity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov